Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Thomas (Cambridge, United Kingdom), E. Symington (Cambridge, United Kingdom), M. Besser (Cambridge, United Kingdom), K. Sheares (Cambridge, United Kingdom). A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE). 1457

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment Source: Eur Respir J 2016; 48: 1369-1376 Year: 2016 Over reliance on D-dimer requests in the diagnosis of venous thromboembolism (VTE) Source: Eur Respir J 2003; 22: Suppl. 45, 220s Year: 2003 Direct oral anticoagulants and venous thromboembolism Source: Eur Respir Rev 2016; 25: 295-302 Year: 2016 Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review Source: Eur Respir Rev, 27 (150) 180094; 10.1183/16000617.0094-2018 Year: 2018 Is venous thromboembolism (VTE) a high risk factor in patients with acute exacerbation of CPOD (AECOPD)? Source: Eur Respir J 2006; 28: Suppl. 50, 178s Year: 2006 Age is a major risk factor of venous thromboembolism (VTE) Source: Annual Congress 2011 - Prediction of pulmonary thromboembolism Year: 2011 Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing Source: Eur Respir J 2016; 47:1313-1314 Year: 2016 Compliance with venous thromboembolic (VTE) risk assessment and prophylaxis in medical inpatients at an English DGH Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019 Year: 2020 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019 Year: 2020 The acquired and inherited risk factors in venous thromboembolism (VTE) Source: Eur Respir J 2003; 22: Suppl. 45, 220s Year: 2003 Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016 Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Anticoagulant treatment of venous thromboembolism: established and new oral agents, remaining questions Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 Factors that predict the risk of recurrent venous thromboembolism (VTE) in patients with VTE and factor V Leiden (FVL) Source: Annual Congress 2010 - Pulmonary embolism Year: 2010 Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients Source: Eur Respir J 2004; 24: Suppl. 48, 273s Year: 2004 Venous thromboembolic (VTE) in patients with ALS: an incidence study Source: Virtual Congress 2021 – Home mechanical ventilation: organisation and outcomes Year: 2021 Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019